Nationwide Experience With Off‐Label Use of Interleukin‐1 Targeting Treatment in Familial Mediterranean Fever Patients

Akar, Servet; Cetin, Pınar; Kalyoncu, Umut; Karadag, Omer; Sari, Ismail; Cınar, Muhammed; Yilmaz, Sedat; Mesut Onat, Ahmet; Kisacik, Bunyamin; Erden, Abdulsamet; Balkarli, Ayse; Kucuksahin, Orhan; Yilmaz Oner, Sibel; Senel, Soner; Tufan, Abdurrahman; Direskeneli, Haner; Oksuz, Ferhat; Pehlivan, Yavuz; Bayindir, Ozun; Keser, Gokhan; Aksu, Kenan; Omma, Ahmet; Kasifoglu, Timucin; Ugur Unal, Ali; Yildiz, Fatih; Ali Balci, Mehmet; Yavuz, Sule; Erten, Sukran; Ozgen, Metin; Sayarlıoglu, Mehmet; Dogru, Atalay; Yildirim, Gozde; Alibaz Oner, Fatma; Engin Tezcan, Mehmet; Nuri Pamuk, Omer; Onen, Fatos

doi:10.1002/acr.23446

Public

Nationwide Experience With Off‐Label Use of Interleukin‐1 Targeting Treatment in Familial Mediterranean Fever Patients

Shared by NobleBlocks on Apr 24, 2018 • 12:00 AM UTC

Authors:

Servet Akar

Pınar Cetin

Umut Kalyoncu

Abstract

Objective Approximately 30–45% of patients with familial Mediterranean fever ( FMF ) have been reported to have attacks despite colchicine treatment. Currently, data on the treatment of colchicine‐unresponsive or colchicine‐intolerant FMF patients are limited; the most promising alternatives seem to...

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!